John, Thomas
Sakai, Hiroshi
Ikeda, Satoshi
Cheng, Ying
Kasahara, Kazuo
Sato, Yuki
Nakahara, Yoshiro
Takeda, Masayuki
Kaneda, Hiroyasu
Zhang, Helong
Maemondo, Makoto
Minato, Koichi
Hisada, Takeshi
Misumi, Yuki
Satouchi, Miyako
Hotta, Katsuyuki
Li, Ang
Oukessou, Abderrahim
Lu, Shun
Funding for this research was provided by:
Bristol Myers Squibb
University of Melbourne
Article History
Received: 3 September 2021
Accepted: 13 January 2022
First Online: 19 February 2022
Declarations
:
: TJ received honoraria from MSD, Bristol Myers Squibb, AstraZeneca, Pfizer, Roche, Novartis, and Amgen; current affiliation: Peter MacCallum Cancer Centre, Dept Medical Oncology, Level 7 VCCC, 305 Grattan St, Melbourne 3000, Australia. HS served an advisory role at Bristol Myers Squibb and Ono Pharmaceutical Co.; and received honoraria from Bristol Myers Squibb and Ono Pharmaceutical Co. Ltd; current affiliation: Ageo Central General Hospital, 1-10-10 Kashiwaza, Ageo-shi, Saitama 362-8588, Japan. SI received research funding from AstraZeneca and Chugai Pharmaceutical Co. Ltd.; and honoraria from Bristol Myers Squibb, Ono, Taiho, AstraZeneca, Chugai Pharmaceutical Co. Ltd, Eli Lilly, Pfizer, and Boehringer Ingelheim. KK received research funding and honoraria from Bristol Myers Squibb and Ono Pharmaceutical Co. Ltd. YS received honoraria from Chugai Pharmaceutical Co. Ltd., MSD, Ono Pharmaceutical Co. Ltd., Novartis, Taiho Pharmaceutical Co. Ltd., AstraZeneca, Bristol Myers Squibb, Nippon Kayaku Co. Ltd., and Pfizer. YN received research funding from Takeda Pharmaceutical Co. Ltd. and Bristol Myers Squibb; and honoraria from Ono Pharmaceutical Co. Ltd., Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, and Chugai Pharmaceutical Co. Ltd.; current affiliation: Kitasato University School of Medicine, 1-15-1, Kitazato, Minami-ku, Sagamihara-shi, Kanagawa 252-0374, Japan. MT received honoraria from Chugai Pharmaceutical Co. Ltd., AstraZeneca K.K., Bristol Myers Squibb, Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd. HK received research funding from Bristol Myers Squibb, Ono Pharmaceutical Co. Ltd., and Eli Lilly; and honoraria from Bristol Myers Squibb, and Ono Pharmaceutical Co. Ltd. MM received honoraria from Ono Pharmaceutical Co. Ltd., and Bristol Myers Squibb. YM received research funding from AstraZeneca, Bristol Myers Squibb, Chugai Pharmaceutical Co. Ltd., and Boehringer Ingelheim. MS received research funding from MSD, Bristol Myers Squibb, Chugai Pharmaceutical Co. Ltd., and AstraZeneca; and honoraria from MSD, Bristol Myers Squibb, Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., AstraZeneca, Eli Lilly, and Taiho Pharmaceutical Co. Ltd. KH received research funding from MSD, AstraZeneca, Chugai Pharmaceutical Co. Ltd., Eli Lilly, and Bristol Myers Squibb; and honoraria from Pfizer, AstraZeneca, Chugai Pharmaceutical Co. Ltd., Eli Lilly, Takeda, MSD, Bristol Myers Squibb, Ono Pharmaceutical Co. Ltd., NipponKayaku, Taiho Pharmaceutical Co. Ltd., and Boehringer Ingelheim. AL and AO are employees and stock owners of Bristol Myers Squibb. SL served advisory roles at AstraZeneca, Pfizer, Boehringer Ingelheim, Hutchison MedPharma, Yuhan Corporation, Menarini, InventisBio, and Roche; received honoraria from AstraZeneca, Roche, Hansoh, and Hengrui Therapeutics; and received research funding from AstraZeneca, Hutchison, Bristol Myers Squibb, Hengrui Therapeutics, Beigene, Roche, and Hansoh. YC, KM, HZ, and TH declare no conflicts of interest.
: This study was conducted according to the Declaration of Helsinki and the international standards of Good Clinical Practice. The study protocol and all amendments were approved by the independent ethics committee or institutional review board of each participating center. All patients provided written informed consent. BMS policy on data sharing may be found at ExternalRef removed.